{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:20:15Z","timestamp":1782937215610,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.eururo.2011.10.043","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T20:32:36Z","timestamp":1320697956000},"page":"928-935","source":"Crossref","is-referenced-by-count":72,"title":["Prospective Randomised Controlled Trial Comparing Trigone-Sparing versus Trigone-Including Intradetrusor Injection of AbobotulinumtoxinA for Refractory Idiopathic Detrusor Overactivity"],"prefix":"10.1016","volume":"61","author":[{"given":"Rustom P.","family":"Manecksha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivor M.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.D.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.10.043_bib0005","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000115409","article-title":"Experience with intradetrusor injection of botulinum toxin-A for treating idiopathic detrusor overactivity in a single Irish institution","volume":"2","author":"Manecksha","year":"2008","journal-title":"Curr Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0015","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0020","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","article-title":"Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial","volume":"103","author":"Sahai","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.10.043_bib0025","first-page":"198","article-title":"Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art","volume":"8","author":"Nitti","year":"2006","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0090-4295(01)01637-5","article-title":"Bladder activation: afferent mechanisms","volume":"59","author":"Andersson","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.10.043_bib0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/nau.20515","article-title":"Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients","volume":"27","author":"Mascarenhas","year":"2008","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.10.043_bib0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.juro.2006.10.047","article-title":"Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux","volume":"177","author":"Karsenty","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0045","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.juro.2010.08.028","article-title":"Botulinum toxin-A injections into neurogenic overactive bladder-to include or exclude the trigone? A prospective, randomized, controlled trial","volume":"184","author":"Abdel-Meguid","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0050","first-page":"3291","article-title":"Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection","volume":"13","author":"Lucioni","year":"2006","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0055","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0060","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.10.043_bib0065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0075","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.juro.2007.03.133","article-title":"Validation of the overactive bladder symptom score","volume":"178","author":"Blavias","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/nau.10066","article-title":"Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies","volume":"21","author":"Schafer","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.10.043_bib0085","unstructured":"R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008."},{"key":"10.1016\/j.eururo.2011.10.043_bib0090","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo-controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/PL00004951","article-title":"Botulinum A toxin: units versus units","volume":"355","author":"Wohlfarth","year":"1997","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0105","first-page":"17","article-title":"Clinical bioequivalence of the current commercial preparations of botulinum toxin","volume":"2","author":"Durif","year":"1995","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.eururo.2011.10.043_bib0110","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s00415-008-0031-7","article-title":"Biological activity of two botulinum toxin type A complexes (Dysport\u00ae and Botox\u00ae) in volunteers: A double-blind, randomized, dose-ranging study","volume":"255","author":"Wohlfarth","year":"2008","journal-title":"J Neurol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811012292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811012292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T10:03:57Z","timestamp":1713089037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811012292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0302283811012292"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.10.043","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.715347851.790902851","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}